Quartz·1 min read·medium
Novartis is buying a U.K. cancer drug startup for up to $1.5 billion
✦AI Summary
Novartis has announced the acquisition of a U.K.-based cancer drug startup for up to $1.5 billion. The deal includes an initial payment of $1.1 billion and additional milestone-based payments to secure a novel antibody-drug conjugate platform.
The Swiss drugmaker will pay $1.1 billion upfront and up to $400 million in milestones to gain a novel antibody-drug conjugate payload platform
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in